Recent Finacing
Recent Raise
Aileron Therapeutics develops cell-penetrating stapled peptides targeting intracellular protein–protein interactions, advancing ALRN-6924 (MDM2/MDMX p53 re-activator) and ALRN-5281 (long-acting GHRH agonist) for oncology and endocrine/metabolic indications.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors